Keele Research Repository

Article

Fernando, IN, Lax, S, Bowden, SJ, Ahmed, I, Steven, JH, Churn, M, Brunt, AM ORCID: https://orcid.org/0000-0002-4797-5097, Agrawal, RK, Canney, P, Stevens, A and Rea, DW (2023) Detailed Sub-study Analysis of the SECRAB Trial: Quality of Life, Cosmesis and Chemotherapy Dose Intensity. Clinical Oncology.

Fernando, IN, Bowden, SJ, Herring, K, Brookes, CL, Ahmed, I, Marshall, A, Grieve, R, Churn, M, Spooner, D, Latief, TN, Agrawal, RK, Brunt, AM ORCID: https://orcid.org/0000-0002-4797-5097, Stevens, A, Goodman, A, Canney, P, Bishop, J, Ritchie, D, Dunn, J, Poole, CJ and Rea, DW (2020) Synchronous versus sequential chemo-radiotherapy in patients with early stage breast cancer (SECRAB): A randomised, phase III, trial. Radiotherapy and Oncology, 142. pp. 52-61.

Earl, HM, Hiller, H, Vallier, A-L, Bowden, SJ, Jordan, SD, Blows, F, Munro, A, Bathers, S, Grieve, R, Spooner, DA, Agrawal, R, Fernando, I, Brunt, AM, O'Reilly, SM, Crawford, SM, Rea, DW, Simmonds, P, Mansi, JL, Stanley, A, McAdam, K, Foster, L, Leonard, RCF, Twelves, CJ, Cameron, D, Bartlett, JMS, Pharoah, P, Provenzano, E, Caldas, C and Poole, CJ (2012) Adjuvant epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) vs CMF in early breast cancer: results with over 7 years median follow-up from the randomised phase III NEAT/BR9601 trials. British Journal of Cancer, 107 (8). pp. 1257-1267.